{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 84,
  "pageCount": 366,
  "prevPage": 83,
  "nextPage": 85,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a Q&A transcript format to build a case against the efficacy of pitolisant based on historical failures at Abbott.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/84",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-84",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Variability is a key flaw in addition to lack of bioavailability; led to \"some patients who see a good peak\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-f91795e9a491",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.34
      },
      "kind": "list",
      "text": "Q&A transcript regarding animal studies, blood-brain barrier penetration, and the decision to terminate the program.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24bf9c2b-17ef-4e33-b7f2-092632e04d6b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.75
      },
      "kind": "list",
      "text": "Q&A transcript regarding FDA review of pitolisant, bioavailability (Cmax/AUC), and inner subject PK variability.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b04a9c8-51ac-4a53-a170-8dbcd23d9743",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.29
      },
      "kind": "paragraph",
      "text": "Blood-brain barrier prevented the drug from reaching the receptors; saw this in animals, primates, and humans; variability in humans was a fatal flaw that led them to terminate the programs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29847413-5d77-431b-b387-4e67bd2b2412",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "Variability is a key flaw in addition to lack of bioavailability; led to \"some patients who see a good peak\"",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6078b89a-cb8c-4ba9-8637-94b1300e075f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Then in animals - we didn't do that in humans - we looked at how it passed the blood-brain barrier and how much landed into the brain. This is by post-mortem extraction. And that's where you look at the problems with variability in passing the blood-brain barriers, so the effect is not reached because you don't reach where the receptors are.\" — Senior pharmaceutical executive/scientist, previously at Abbott and now at another major pharma company",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9ccf-ffe68fafb152",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00084687-5aba-4fbb-8241-f94ac6a5c384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Abbott faced problems in passing the blood-brain barrier in rodents, primates, and humans - \"you don't reach where the receptors are.\" The \"huge variability\" in drug concentration in the blood - in human subjects, where some would see \"a good peak\" - was another flaw that led them to terminate the program, as they knew it was unsolvable from their long experience in the histamine receptor space. He stated pitolisant has the same bioavailability and variability issues.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2774d040-44eb-426c-b73e-3365893f81df",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}